Dr. Sarah Flanagan Wesley graduated from medical school at the Royal College of Surgeons in Dublin, followed by residency in adult neurology at the Icahn School of Medicine at Mount Sinai where she was chief resident at Mount Sinai Beth Israel. She completed a fellowship in neuroimmunology at the Yale School of Medicine and then served on faculty at Yale as an Assistant Professor of Neurology, working in the neuroimmunology subdivision. At Yale she collaborated on early initiatives related to the study of immune-related adverse events to cancer immunotherapies. In 2020 she moved to Columbia University where she is currently an Assistant Professor of Neurology. She coordinates neurological management of and research on immunotoxicity from various forms of cancer immunotherapy, in particular CAR T-cell therapy and immune checkpoint inhibitors. She has published on safety of CAR T-cell therapy and management of ICANS, and she continues to manage neurological complications from all patients receiving CAR T-cell therapy.
Sarah Flanagan Wesley, MD, MPH
